Drug Profile


Alternative Names: SM 1

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sequential Medicine Ltd
  • Class Acetamides; Anxiolytics; Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists; Histamine H1 receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 01 Jun 2016 Sequential Medicine completes a phase II trial in Insomnia in USA (NCT02671760)
  • 01 Feb 2016 Phase-II clinical trials in Insomnia in USA (PO) (NCT02671760)
  • 20 Jan 2016 Sequential Medicine plans a phase II trial for Insomnia (short-term) in USA (NCT02671760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top